A Phase I dose escalation clinical study to evaluate the safety and efficacy of ALLO-ASC (Allogenic adipose-derived stem cells) in the patients with Crohn's fistula
Latest Information Update: 28 Aug 2023
At a glance
- Drugs Adipose stem cell therapy Anterogen (Primary)
- Indications Rectal fistula
- Focus Adverse reactions
- Sponsors Anterogen
- 23 Aug 2023 Status changed from recruiting to completed.
- 15 Dec 2013 New trial record